POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS
Clinical trials for POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS explained in plain language.
Never miss a new study
Get alerted when new POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS trials appear
Sign up with your email to follow new studies for POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with arthritis: Long-Term drug study launches
Disease control Recruiting nowThis study is testing the long-term safety and effectiveness of the drug filgotinib in children and adolescents aged 8 to 17 with juvenile idiopathic arthritis. Participants must have already completed a previous filgotinib study and shown improvement. The goal is to see if the d…
Matched conditions: POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS
Phase: PHASE3 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New study tracks xeljanz safety in kids with arthritis
Disease control Recruiting nowThis study looks at the safety and effectiveness of the drug Xeljanz in children aged 2 to 17 with active juvenile idiopathic arthritis or juvenile psoriatic arthritis. It is an observational study in Korean clinics, meaning doctors prescribe the drug as usual and researchers mon…
Matched conditions: POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS
Sponsor: Pfizer • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Engineered immune cells aim to tame childhood arthritis and lupus
Disease control Recruiting nowThis early-phase trial is testing a new treatment called KN5601, which uses a patient's own immune cells (NK cells) that have been engineered to target and destroy harmful B cells. The goal is to see if it is safe and can help children aged 5 and older with rheumatic diseases lik…
Matched conditions: POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Engineered immune cells aim to tame childhood autoimmune diseases
Disease control Recruiting nowThis early-stage trial tests a new type of CAR-T cell therapy in 11 children with severe rheumatic diseases like juvenile dermatomyositis and arthritis that haven't improved with standard treatments. The therapy uses specially engineered immune cells to target and calm the overac…
Matched conditions: POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS
Phase: PHASE1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 18:49 UTC